BioNeutral Group Passes Final Key GLP Efficacy Test for Registration as a Hospital Sporicide in Canada and Australia

BioNeutral's Ygiene™ Passes the Difficult Sporicide Test in Only 20 Minutes, Thus Completing the GLP Test Requirements for Product Approvals

BioNeutral Group, Inc. (OTCBB:BONU), a specialty chemical technology-based life science company, reports that it has received test results from ATS Labs indicating that its Ygiene™ hospital-grade antimicrobial has passed the stringent sporicidal GLP test requirements for hospital and medical environment sporicide efficacy claims in Canada and Australia.

This key test demonstrated that Ygiene™ hospital-grade antimicrobial eliminated harmful spores in only 20 minutes. With the completion of the required GLP testing, BioNeutral is now positioned to apply for approval of its Ygiene™ hospital-grade antimicrobial as a bactericide, fungicide and sporicide with Health Canada under the Food and Drug Act and in Australia with the Department of Health and Aging Therapeutic Goods Administration. BioNeutral Group intends to proceed with these approvals and commercialize Ygiene™ hospital-grade antimicrobial in these countries.

Dr. Andy Kielbania, Chief Scientist at BioNeutral, stated: “We are extremely pleased with these test results for Ygiene™, which show that we have a rapid-acting sporicide. We look forward to entering the important markets of Canada and Australia in addition to Germany and the United Kingdom.”

About ATS Labs
ATS Labs is a leading internationally recognized independent testing laboratory used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial services and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the US, Canada and around the world.

About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a specialty chemical technology-based life science company that is developing and intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous microorganisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene™ and Ogiene™, are both eco-friendly. The Company has combined these widely used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral’s proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the Ygiene™ brand have not yet been submitted to the EPA for approval for sale in the United States; however they have been approved in Germany and are allowed in the UK, France and Sweden.

Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene™ and are not yet available for sale in the United States.

Source: Business Wire/Yahoo Finance